catalog number :
MBS370005
products full name :
AMACRacemase RMab
products short name :
AMACRacemase
products name syn :
AMACRacemase RMab
other names :
Alpha-methylacyl-CoA racemase; Alpha-methylacyl-CoA racemase; alpha-methylacyl-CoA racemase; OTTHUMP00000115916; OTTHUMP00000115917; OTTHUMP00000219978; OTTHUMP00000219979; OTTHUMP00000219980; 2-methylacyl-CoA racemase; alpha-methylacyl-CoA racemase; 2-methylacyl-CoA racemase
products gene name :
AMACRacemase
other gene names :
AMACR; AMACR; RM; RACE; CBAS4
uniprot entry name :
AMACR_HUMAN
form :
P504S/AMACR is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
storage stability :
Store at 2 to 8 degree C in the dark.
other info1 :
Control: Prostatic Adenocarcinoma. Localization: Cytoplasmic
other info2 :
Reactivity Note: Paraffin, Frozen
products description :
AMACR (P504S) is an acronym for the protein alpha-methylacyl CoA racemase that helps to metabolize certain fatty acids within the body. AMACR has been recently described as a prostate cancer-specifi c gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. Expression of AMACR protein is found in Prostatic Adenocarcinoma but not in benign prostatic tissue. It stains premalignant lesions of the prostate: High-Grade Prostatic Intraepithelial Neoplasia (PIN) and Atypical Adenomatous Hyperplasia. Several studies have suggested that AMACR can be used as a prostate cancer biomarker.High expression of AMACR (P504S) protein is usually found in Prostatic Adenocarcinoma but not in benign prostatic tissue by immunohistochemical staining in paraffin-embedded tissues. Using AMACR as a positive marker along with basal-cell staining (34betaE12 or p63) as a negative marker could help to confirm the diagnosis of small foci of Prostate Carcinoma on needle biopsies.
ncbi mol weight :
42,387 Da
ncbi pathways :
Beta-oxidation Of Pristanoyl-CoA Pathway 106138!!Bile Acid And Bile Salt Metabolism Pathway 106144!!Metabolic Pathways 132956!!Metabolism Of Lipids And Lipoproteins Pathway 160976!!Peroxisomal Lipid Metabolism Pathway 106136!!Peroxisome Pathway 131226!!Peroxisome Pathway 131126!!Primary Bile Acid Biosynthesis Pathway 82938!!Primary Bile Acid Biosynthesis Pathway 299!!Synthesis Of Bile Acids And Bile Salts Pathway 106145
ncbi summary :
This gene encodes a racemase. The encoded enzyme interconverts pristanoyl-CoA and C27-bile acylCoAs between their (R)- and (S)-stereoisomers. The conversion to the (S)-stereoisomers is necessary for degradation of these substrates by peroxisomal beta-oxidation. Encoded proteins from this locus localize to both mitochondria and peroxisomes. Mutations in this gene may be associated with adult-onset sensorimotor neuropathy, pigmentary retinopathy, and adrenomyeloneuropathy due to defects in bile acid synthesis. Alternatively spliced transcript variants have been described. Read-through transcription also exists between this gene and the upstream neighboring C1QTNF3 (C1q and tumor necrosis factor related protein 3) gene. [provided by RefSeq]
uniprot summary :
Function: Racemization of 2-methyl-branched fatty acid CoA esters. Responsible for the conversion of pristanoyl-CoA and C27-bile acyl-CoAs to their (S)-stereoisomers. Catalytic activity: (2S)-2-methylacyl-CoA = (2R)-2-methylacyl-CoA. Pathway: Lipid metabolism; bile acid biosynthesis.Lipid metabolism; fatty acid metabolism. Subcellular location: Peroxisome. Mitochondrion Ref.1. Involvement in disease: Defects in AMACR are the cause of alpha-methylacyl-CoA racemase deficiency (AMACRD) [. MIM:604489]. AMACRD results in elevated plasma concentrations of pristanic acid C27-bile-acid intermediates. It can be associated with polyneuropathy, retinitis pigmentosa, epilepsy. Ref.2Defects in AMACR are the cause of congenital bile acid synthesis defect type 4 (CBAS4) [. MIM:214950]; also known as cholestasis, intrahepatic, with defective conversion of trihydroxycoprostanic acid to cholic acid or trihydroxycoprostanic acid in bile. Clinical features include neonatal jaundice, intrahepatic cholestasis, bile duct deficiency and absence of cholic acid from bile. Ref.2 Ref.11. Sequence similarities: Belongs to the CaiB/BaiF CoA-transferase family. Sequence caution: The sequence ACL67853.1 differs from that shown. Reason: Aberrant splicing.The sequence ACL67854.1 differs from that shown. Reason: Aberrant splicing.The sequence CAB44062.1 differs from that shown. Reason: Frameshift at positions 62, 65 and 114.